Point72 Asia Singapore Pte. Ltd. Takes $84,000 Position in Mural Oncology plc (NASDAQ:MURA)

Point72 Asia Singapore Pte. Ltd. bought a new position in Mural Oncology plc (NASDAQ:MURA) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 26,642 shares of the company’s stock, valued at approximately $84,000.

Several other large investors have also recently modified their holdings of MURA. Armistice Capital LLC purchased a new stake in Mural Oncology in the 2nd quarter worth about $5,300,000. Acadian Asset Management LLC bought a new position in Mural Oncology in the 2nd quarter valued at $998,000. Primecap Management Co. CA bought a new stake in shares of Mural Oncology during the second quarter worth $740,000. Renaissance Technologies LLC purchased a new stake in shares of Mural Oncology during the second quarter valued at $729,000. Finally, Squarepoint Ops LLC bought a new position in shares of Mural Oncology in the second quarter worth about $526,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Stock Performance

MURA stock opened at $3.36 on Friday. Mural Oncology plc has a 1-year low of $2.88 and a 1-year high of $17.00. The business has a 50-day moving average price of $3.25 and a 200 day moving average price of $3.53.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($1.90) by $0.04. On average, equities analysts anticipate that Mural Oncology plc will post -7.54 EPS for the current year.

Insider Buying and Selling

In other Mural Oncology news, CEO Caroline Loew sold 12,531 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $2.91, for a total transaction of $36,465.21. Following the sale, the chief executive officer now owns 240,391 shares of the company’s stock, valued at approximately $699,537.81. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on MURA. Rodman & Renshaw initiated coverage on shares of Mural Oncology in a research report on Friday, June 28th. They issued a “buy” rating and a $15.00 price objective for the company. Raymond James started coverage on Mural Oncology in a research note on Friday. They issued a “strong-buy” rating and a $18.00 price objective on the stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.